eNose device shows promise in detecting prostate cancer
In comparison to the cohort of highly trained dogs, the eNose instrument was found to have sensitivity of 85.2% and specificity of 79.1%.
Related Articles
Nivolumab plus chemotherapy nears EU approval for urothelial carcinoma
A decision regarding EU marketing authorization is expected by June 2024.
2024 AUA preview: Dr. Wymer on top research in stone disease
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
siRNA drug therapy shows promise in clear cell renal cell carcinoma
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
2024 AUA preview: Dr. Elterman on key research in BPH
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Dr. Matin discusses early work with FGFR inhibition in localized UTUC
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
FDA approves pivmecillinam tablets for uncomplicated UTIs
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…
AUA 2024: Dr. Weiner previews key prostate cancer research
Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.
Use of PDE-5 inhibitors and beta-3 agonists in treating BPH
“Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH,” says Eiftu S. Haile, MD.
Cystoscope Preferences and Practices in Urology
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Enzalutamide granted approval in EU for nmHSPC
The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with…